Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Part of paid clinical trials in Princeton, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02856451
Status
Completed

Conditions

  • Encephalitis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.

Key Dates

Start date
Dec 9, 2015
Status verified
Jun 2022
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
486 participants (actual)

Arms

  • Arm: Patients Treated with Nivolumab followed by Encephalitis Event
    Case series reported to the sponsor from various health care facilities

Primary Outcome Measure

Outcomes of Encephalitis [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Local InstitutionPrincetonNew Jersey08540-

Find similar trials in Princeton, NJ

By research site
Local Institution· Princeton, NJ

Related Studies